Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines
- 21 August 2006
- Vol. 24, S227-S232
- https://doi.org/10.1016/j.vaccine.2006.05.102
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus VaccineNew England Journal of Medicine, 2006
- Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus GastroenteritisNew England Journal of Medicine, 2006
- Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial NeoplasiaObstetrics & Gynecology, 2006
- Improving adolescent health: Focus on HPV vaccine acceptanceJournal of Adolescent Health, 2005
- Cost-Effectiveness of Cervical-Cancer Screening in Five Developing CountriesNew England Journal of Medicine, 2005
- The Promise of Global Cervical-Cancer PreventionNew England Journal of Medicine, 2005
- Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for ScreeningObstetrics & Gynecology, 2004
- American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and CancerCA: A Cancer Journal for Clinicians, 2002
- Drugs in PregnancyNew England Journal of Medicine, 1998